Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification
The ADSs continue trading on the Nasdaq Capital Market, subject to compliance with other applicable listing requirements.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Genenta Science (Nasdaq: GNTA) received a Nasdaq notification on October 16, 2026, that it failed the minimum bid price requirement. Its American Depositary Shares (ADSs) closed below $1.00 for 30 consecutive business days, from September 3 through October 15, 2026.
The notice does not cause immediate delisting. Genenta has until April 14, 2027 to regain compliance, requiring a closing bid of at least $1.00 per ADS for at least 10 consecutive business days, unless Nasdaq extends that period. An additional 180-calendar-day compliance period is conditional on eligibility requirements. Shareholders have already approved a 1-for-10 to 1-for-20 reverse split, which the board may implement if appropriate. Genenta plans to monitor its ADS price and evaluate compliance options.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Minor pointNo immediate delisting results from the notice; ADSs continue trading subject to other applicable listing requirements.
Negative
- Major pointMinimum bid price deficiency follows 30 consecutive business days with ADS closing bids below $1.00.
- Moderate point. Forward-looking: it has not happened yet and may not happen.April 14, 2027 deadline requires at least $1.00 per ADS for at least 10 consecutive business days, unless Nasdaq extends that period.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional 180-calendar-day period depends on meeting eligibility requirements and written notice of intent to cure the deficiency.
Key Figures
- Minimum bid-price threshold
- $1.00 per share
- Nasdaq Listing Rule 5550(a)(2)
- Duration below threshold
- 30 consecutive business days
- September 3 through October 15, 2026
- Initial compliance period
- 180 calendar days; until April 14, 2027
- Deadline to regain compliance
- Compliance restoration test
- At least $1.00 per ADS for 10 consecutive business days
- Required to regain compliance
- Potential additional compliance period
- 180 calendar days
- Conditional on meeting applicable requirements
- Approved reverse stock split range
- 1-for-10 to 1-for-20
- Shareholders approved; Board authorized to implement
Key Terms
reverse stock split financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MILAN, Italy, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) (the “Company”) today announced that on October 16, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement of
The notification was issued because the closing bid price of the Company’s American Depositary Shares (“ADSs”) was below
Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, until April 14, 2027, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s ADSs must be at least
If the Company does not regain compliance by April 14, 2027, it may be eligible for an additional 180-calendar-day compliance period, provided that it satisfies the applicable market value of publicly held shares requirement and all other initial listing standards for the Nasdaq Capital Market, except the minimum bid price requirement, and provides written notice of its intention to cure the deficiency, including by effecting a reverse stock split, if necessary.
As previously disclosed, the Company’s shareholders have already approved a reverse stock split within a range of 1-for-10 to 1-for-20, which the Board of Directors is authorized to implement, if deemed appropriate.
The Company intends to monitor the closing bid price of its ADSs and evaluate available options to regain compliance with Nasdaq’s minimum bid price requirement. Although the Company will use all reasonable efforts, there can be no assurance that it will regain compliance within the initial compliance period, qualify for any additional compliance period, or otherwise remain in compliance with other Nasdaq continued listing requirements.
About Genenta Science
Genenta Science (Nasdaq: GNTA) is evolving into a next-generation strategic consolidator focused on privately held specialized companies operating in Italian national security-regulated sectors, with activities spanning cybersecurity, defense, aerospace, and biotechnology/biosecurity. Genenta holds a
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the Company’s intentions and ability to regain compliance with Nasdaq’s minimum bid price requirement and maintain its Nasdaq listing. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including fluctuations in the market price of the Company’s ADSs and the Company’s ability to satisfy Nasdaq’s continued listing requirements. Additional risks and uncertainties are described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by applicable law.
Investor Relations Genenta Science S.p.A. Tiziana Pollio, Mobile: +39 348 23 15 143 email: tiziana.pollio@genenta.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Genenta Science (GNTA) receive a Nasdaq deficiency notice?
Genenta received the notice because its ADS closing bid price remained below $1.00 for 30 consecutive business days, from September 3 through October 15, 2026. This breached Nasdaq Listing Rule 5550(a)(2). The notice does not result in immediate delisting.
When must Genenta Science (GNTA) regain Nasdaq minimum bid price compliance?
Genenta has an initial 180-calendar-day period ending April 14, 2027 to regain compliance. Its ADS closing bid must be at least $1.00 for a minimum of 10 consecutive business days during that period, unless Nasdaq exercises its discretion to extend the required period.
What conditions apply to an additional Nasdaq compliance period for Genenta Science (GNTA)?
An additional 180-calendar-day compliance period may be available if Genenta meets the applicable market value of publicly held shares requirement and all other Nasdaq Capital Market initial listing standards except minimum bid price. It must also give written notice of its intention to cure the deficiency, including through a reverse stock split if necessary.